A doctor can offer a treatment only if it belongs to the world of possibilities inside the consulting room. That sounds obvious. Clinical research makes it surprisingly complicated. A trial may exist, a patient may be suitable, and the two may still never meet. Javara has built a company around closing that distance.
- Put research staff inside existing healthcare practices.
- Give physicians operational support and patients a local guide.
- Deliver industry-sponsored studies through those established relationships.
Its proposition is wonderfully physical: put the people who run research where people receive care. The company calls itself an integrated research organization, or IRO. Beneath the acronym sits a staffing and infrastructure business, with a theory about trust. An invitation from a familiar medical team arrives differently from an advertisement for a study.
The briefcase came first
Jennifer Byrne did not enter research through a grand founding revelation. In a published recollection, she describes turning up for her first job after college believing she was becoming a pharmaceutical sales representative. She wore a suit and carried a briefcase her family had given her. The job was in clinical research.
“I had found my life’s work,” she recalled. Byrne later became CEO of PMG Research. In 2018, she founded Javara with Amanda Wright and Linda McCarty. Their company would put research inside healthcare organizations, combining local teams with shared operating resources. The founders brought experience of the machinery they wanted to rearrange.
A research team down the hall
For a healthcare organization, the obstacle is often capacity. A clinic has patients, medical records and clinicians. Running trials also requires trained research personnel, compliance processes, technology and reliable data capture. Those functions must fit around an already busy practice. An available doctor is not automatically an operating research site.
Javara supplies that missing layer. It employs research staff and embeds them alongside existing care teams. Its Clinical Trial Navigators support patients through the research process. Centralized systems and standardized operations handle work that would otherwise have to be assembled practice by practice. The model adapts to partners’ existing systems and electronic health records.
Existing care relationships
Shared study operations
and ongoing support
Commercially, this places Javara between healthcare delivery and the companies developing medicines. Biopharma sponsors and contract research organizations need sites that can execute studies. Healthcare partners want research capability without constructing every component themselves. Patients need understandable opportunities and practical support. Javara’s service connects those requirements at the clinic.
Its alternative is the standalone research site, another site network, or a health system developing its own program. The distinction is where operations live and how patients encounter them. Javara makes the existing healthcare relationship part of trial delivery. A CRO can therefore be a customer or collaborator, rather than simply a rival.
The patient-facing offer is concrete. Javara’s listings are organized by location and condition, with study requirements and, where applicable, compensation. A person can check whether a nearby study might fit before contacting the research team. The menu includes conditions such as diabetes and hypothyroidism, alongside cardiovascular studies. Availability and eligibility remain specific to each protocol.
Someone still pays for the people
Javara tells healthcare partners they need make no direct investment in research staff or infrastructure; it assumes much of that financial risk. This is consequential. The company’s offer involves employing people and supporting study operations before a partner could reasonably expect a functioning research business.
Outside capital has helped finance expansion. General Atlantic invested through a Series B announced in April 2022. A Series C followed in May 2025. A Triad Business Journal report excerpted by Javara put that investment at approximately $6.6 million. The company said the funding would support healthcare partnerships and additional therapeutic specialties.
That distinction deserves space. A health system’s patient population describes an opportunity. A study’s eligibility criteria determine who might qualify; screening and a patient’s decision determine who joins. Counting people in a network cannot establish how many received an experimental treatment, completed a trial or benefited from it.
The first objection was the calendar
Physician hesitation is documented in an AMGA best-practices account: time and compensation were early concerns. Privia physician Charlotte Grayson-Mathis described patient enthusiasm and research publications helping colleagues take notice. Her experience suggests that acceptance grows through visible work inside the practice. Even with support, doctors still need to commit effort and sometimes adjust schedules.
“We now consider our Javara team to be an extension of our practice.”Charlotte Grayson-Mathis, MD · Privia Health
The transferable lesson is operational: begin with willing clinicians, agree on responsibilities and match studies to the organization’s capabilities. Shared infrastructure helps when local workflows can accommodate it. A disengaged investigator, an unsuitable patient population or an awkward arrangement of facilities can limit what is feasible. Proximity alone cannot run a protocol.
The company’s stated values - teamwork, ownership and trustworthiness - fit a service that depends on coordination. An embedded team has to work within another organization’s routines while meeting the demands of a sponsored study. Its expertise lies partly in making those responsibilities legible: who supports the patient, who captures the data and how research joins the working day.
Fayetteville puts the idea to work
Javara announced its Cape Fear Valley Health partnership in July 2025. In February 2026 came its first oncology trial award, alongside the health system and Cape Fear Valley Research Institute. The study concerns triple-negative breast cancer, with Kenneth Manning as principal investigator. It brings a specific research opportunity into southeastern North Carolina community care.
May 2026 brought a Texas Health Resources collaboration, initially targeting cardiovascular and cardiometabolic disease, gastroenterology and internal medicine. The announcement described a health system with 29 hospital locations and more than 420 access points. Those figures describe the partner’s footprint, rather than a claim that every location immediately became a trial site.
In September 2026, commercial chief John Worden addressed AI-assisted recruitment. His argument kept the physician in the picture: technology and health-record data can help identify potential matches, while clinical relationships help patients understand the opportunity. For Javara, better matching belongs inside an operating system of people, governance and care.
Javara subsequently announced inclusion in the 2026 Inc. 5000. Its more interesting test remains local: can a particular clinic consistently make research workable? Patients can start with its location-based trial listings. Healthcare leaders can examine its partnership model. Sponsors can consider the network as a route into community practices. The premise comes back to that consulting room: an option has to arrive before anyone can choose it.